 |
11 Diseases |  |
2 Trials |
|
2 Trials |  |
1263 News |  |
| «12...567891011121314151617» |
- Dificid (fidaxomicin) / Merck (MSD), Astellas
Implications of C. difficile Treatment on Environmental Contamination: A Randomized Controlled Trial with Microbiologic, Environmental, and Molecular Outcomes (144 ABC) - Sep 12, 2019 - Abstract #IDWeek2019IDWeek_647;
Treatment choice may have a role in reducing C. difficile contamination of the hospital environment. Further study is needed to assess for effect on disease incidence.
- | Dificid (fidaxomicin) / Merck (MSD), Astellas
Journal: Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses. (Pubmed Central) - Sep 8, 2019
P3b/4
Subgroup analyses from the EXTEND study suggest that EPFX is efficacious as a potential treatment for CDI regardless of age, cancer diagnosis, infection with PCR-ribotype 027, CDI severity or prior CDI. ClinicalTrials.gov identifier: NCT02254967.
- | Dificid (fidaxomicin) / Merck (MSD), Astellas
New trial: Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI) (clinicaltrials.gov) - Aug 28, 2019
P, N=50, Active, not recruiting, Sponsor: University of Pittsburgh
- Dificid (fidaxomicin) / Merck (MSD), Astellas
Clostridioides difficile infection (CDI) in solid organ (SOT) and hematopoietic stem cell transplant (HCT) recipients: a prospective multinational study () - Aug 26, 2019 - Abstract #IDWeek2019IDWeek_3079;
Higher recurrence rates were associated with metronidazole-only regimen (OR: 4.6, 95%CI: 1.6-12.8; p=0.004) and a history of CMV after transplant (OR: 5.2, 95%CI: 1.7-15.7; p=0.003).Conclusion : Despite their immunosuppressed state, recurrence, ICU admission and mortality occurred in a minority of SOT and HCT with CDI. Initial use of metronidazole and CMV viremia/disease were associated with higher recurrence rates.
- Dificid (fidaxomicin) / Merck (MSD), Astellas
First-line Fidaxomicin Use in High Risk Inpatients Reduces Recurrence Rates () - Aug 26, 2019 - Abstract #IDWeek2019IDWeek_2843;
Global cure and CDI upon readmission also improved in the post-group (Table 1). In patients receiving partial courses of fidaxomicin, recurrence (9.3% vs 25%, P=0.19), global cure (86% vs 75%, P=0.44), and infection on readmission (28.6% vs 37.5%, P=0.67) were similar.Conclusion : Fidaxomicin as a first line agent in high risk CDI patients decreased recurrence and increased global cure.
- vancomycin / generics
One Dose Vancomycin Prophylaxis for In-Hospital Clostridioides difficile - Associated Disease () - Aug 26, 2019 - Abstract #IDWeek2019IDWeek_2829;
Recent reports suggest that prophylactic administration of vancomycin or fidaxomicin might reduce in-hospital CDAD incidence...OVP group received ≥ 1 dose of vancomycin 125 mg once per day.Results : Patients within OVP group (122; 25.2%) had higher age adjusted Charlson comorbidity index (CCI) (8; IQR 6-10 vs. 6; 5-8), were more often hospitalized within 3 months (62; 50.8% vs. 121; 33.4%), more commonly received piperacillin/tazobactam (60; 49.2% vs. 81; 22.4%) and carbapenems (27; 22.1% vs. 43; 11.9%) with longer duration of antibiotic therapy (14; 10-20 vs 10; 10-14 days)...Only CDAD during index hospitalization was associated with 90-day readmission (HR 4.60; 95%CI 1.93-10.96).Conclusion : Primary OVP was highly effective in reducing the risk of in-hospital CDAD in elderly patients treated with systemic antimicrobial therapy. Prospective studies with follow-up are needed to define long-term efficacy and potential risks of this strategy.
- Dificid (fidaxomicin) / Merck (MSD), Astellas
Incidence of Clostridioides Difficile Infection Among United States Medicare Advantage Enrollees () - Aug 26, 2019 - Abstract #IDWeek2019IDWeek_2799;
CDI patients were more likely than non-CDI patients to be older (mean age, 78.3 vs 76.1 y, P < 0.0001), be women (64.5% vs 58.1%, P < 0.0001), or have comorbidities (mean Charlson comorbidity index score, 4.5 vs 1.8, P < 0.0001).Conclusion : CDI incidence rates in the Medicare Advantage population were similar to those reported previously in the Medicare fee-for-service population and nationally among adults aged ≥ 65 years. Data are consistent with a high CDI burden among older US adults.Funding: Pfizer
- Dificid (fidaxomicin) / Merck (MSD), Astellas
Impact of Two-Step Testing on the Diagnosis and Management of Clostridium difficile in a Multi-Hospital Healthcare System () - Aug 26, 2019 - Abstract #IDWeek2019IDWeek_2403;
Anti-CDI agents included fidaxomicin, metronidazole and oral vancomycin, but may have included non-CDI indications for metronidazole.Results : A total of 115 HO-CDI cases were identified; 91 (79%) before and 24 (21%) after. Use of a two-step approach for CDI testing reduced HO-CDI rates, but did not have a significant impact on anti-CDI antibiotic use in a multi-hospital community health system.
- Dificid (fidaxomicin) / Merck (MSD), Astellas
Impact of Updated IDSA Clostridium difficile Guidelines on the use of Fidaxomicin in a Large Health System () - Aug 26, 2019 - Abstract #IDWeek2019IDWeek_2402;
Dissemination of new guidelines to providers should be a key function of ASPs as well as monitoring for changes in usage after implementation of local changes. Further studies are needed to define any differences in practice patterns and clinical outcomes related to changes in guidelines.
- Dificid (fidaxomicin) / Merck (MSD), Astellas
Adherence versus Non-adherence: Clinical Outcomes of an Antimicrobial Stewardship Directed Treatment Protocol for Clostridioides difficile Infection () - Aug 26, 2019 - Abstract #IDWeek2019IDWeek_2398;
An overall protocol adherence rate of 53% is consistent with previous published literature. Future direction to develop an EHR order set with targeted recommendations is anticipated to further improve adherence and clinical outcomes.
- Zinplava (bezlotoxumab) / Merck (MSD)
Bezlotoxumab administered at the end of a suppressive drug regimen for patients with multiply recurrent Clostridioides difficile infection () - Aug 26, 2019 - Abstract #IDWeek2019IDWeek_2087;
One of the patients had long-standing underlying irritable bowel syndrome and variable initial response to re-starting vancomycin. The other patient responded to re-starting fidaxomicin.Conclusion : Bezlotoxumab at the end of a prolonged suppressive treatment regimen may be an effective therapeutic strategy in preventing recurrent CDI in complicated, multiply recurrent CDI patients.
- vancomycin / generics
Vancomycin 125 mg Versus 250 mg for the Treatment of Non-Severe and Severe Clostridium difficile Infections () - Aug 26, 2019 - Abstract #IDWeek2019IDWeek_2084;
Furthermore, the dose of vancomycin did not have a significant effect on duration of symptoms, relapse, or 30-day all-cause mortality. Using the lower, guideline recommended dose of vancomycin could potentially reduce patient exposure and provide cost-savings benefits without sacrificing efficacy.
- Dificid (fidaxomicin) / Merck (MSD), Astellas
Impact of updated IDSA practice guidelines on the treatment of Clostridium difficile infections in the United States () - Aug 26, 2019 - Abstract #IDWeek2019IDWeek_1545;
IDSA should provide more timely updates to practice guidelines as new data emerge. Annual or bi-annual updates posted in electronic or other non-traditional formats may be more efficient than publishing long-form articles.
- Xerava (eravacycline) / Tetraphase
In vitro Activity of Eravacycline, a New Tetracycline Analog, and Comparators Against the Six Most Commonly Isolated Ribotypes of Clostridioides difficile () - Aug 26, 2019 - Abstract #IDWeek2019IDWeek_1449;
difficile isolates. These data provide insight into why patients given eravacycline had a low likelihood of developing CDI and support further research to better understand the use of eravacycline to prevent or potentially treat patients with CDI.
- Flagyl (metronidazole) / SLA, ridinilazole (SMT 19969) / Summit Therapeutics
RIDINILAZOLE REDUCES RECURRENCE OF CLOSTRIDIUM DIFFICILE INFECTION WITH MINIMAL IMPACT ON THE GUT MICROBIOTA (Barcelona) - Aug 18, 2019 - Abstract #UEGW2019UEGW_2083;
Preservation of the microbiome likely contributed to the low rate of recurrence, and superior efficacy on SCR, compared to vancomycin. Further clinical development is warranted.
- Dificid (fidaxomicin) / Merck (MSD), Astellas, Zinplava (bezlotoxumab) / Merck (MSD)
FMT in clinical practice for C. difficile infection: Pro (F3) - Aug 18, 2019 - Abstract #UEGW2019UEGW_108;
Donors are also included in the folllow-up to recognise diseases of which transmission to donors could be possible. In summary, FMT will remain as the first treatment choice for patients with rCDI, unless new regulations will classify donor feces suspensions as a drug or pharmaceutical product.
- | Dificid (fidaxomicin) / Merck (MSD), Astellas
Journal: Tiacumicin Congeners with Improved Antibacterial Activity from a Halogenase-Inactivated Mutant. (Pubmed Central) - Aug 17, 2019
Tiacumicin B (1, also known as fidaxomicin or difimicin) is a marketed drug for the treatment of Clostridium difficile infections...Herein we report the isolation, structure elucidation, and bioactivity evaluation of 14 tiacumicin congeners (including 11 new ones) from the tiaM-inactivated mutant. A new tiacumicin congener, 3, with a propyl group at C-7‴ of the aromatic ring was found to exhibit improved antibacterial activity.
- | Flagyl (metronidazole) / SLA
Journal: Management of Clostridium difficile infections at German intensive care units - results from a survey among intensivists (Pubmed Central) - Aug 17, 2019
A new tiacumicin congener, 3, with a propyl group at C-7‴ of the aromatic ring was found to exhibit improved antibacterial activity. Our survey indicated a high awareness of German intensivists for Clostridium difficile infections, but also marked differences in local therapeutic algorithms, especially in first-line treatment.
- | Flagyl (metronidazole) / SLA, Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, Avelox (moxifloxacin) / Bayer
Clinical, Journal: Trends of Antimicrobial Susceptibility of Clostridium difficileIsolates in West China Hospital of Sichuan University from 2015 to 2017 (Pubmed Central) - Aug 16, 2019
Clostridium difficileis highly resistant to clindamycin and quinolones. Since strains remain highly sensitive to metronidazole and vancomycin in our hospital, empirical application is reasonable without routine antimicrobial susceptibility testing.
- | Dificid (fidaxomicin) / Merck (MSD), Astellas
Journal: The effect of using Fidaxomicin on recurrent Clostridium difficile infection? (Pubmed Central) - Aug 15, 2019
There were mixed results with using fidaxomicin for severe CDI, with only 42% of patients responding. Our results suggest fidaxomicin is best suited as a treatment for mild CDI during a patient's first episode.
- Flagyl (metronidazole) / SLA, ceftriaxone / Generic Mfg.
Treatment of Severe Clostridioides difficile Infection With Intravenous Immunoglobulin (Exhibit Halls 3 and 4 (Street Level)) - Aug 8, 2019 - Abstract #ACG2019ACG_1578;
Her hospital course was long and complicated, requiring trials of multiple antibiotics: ceftriaxone, metronidazole, piperacillin-tazobactam, and ertapenem...Despite 5 days of oral vancomycin, symptoms did not regress...Fidaxomicin was started...Moreover, IVIG may prove to be cost-effective by preventing severe or recurrent disease. In cases of CDI refractory to standard antibiotic treatment, passive immunity with IVIG may be a reasonable adjunct to standard therapy.
- Flagyl (metronidazole) / SLA
Use of Intravenous Immunoglobulin as a Treatment Adjunct for Refractory Clostridioides difficile Infection (Exhibit Halls 3 and 4 (Street Level)) - Aug 8, 2019 - Abstract #ACG2019ACG_1562;
We suggest consideration for incorporating IVIG therapy in difficult to manage CDI regardless of immunoglobulin status. A need remains for randomized control trials to better establish the optimal timing and dosing of IVIG in the treatment of CDI.
- Flagyl (metronidazole) / SLA
Failed Fecal Microbiota Transplantation for Fulminant C. difficile Colitis With Toxic Megacolon (Exhibit Halls 3 and 4 (Street Level)) - Aug 8, 2019 - Abstract #ACG2019ACG_1517;
The mechanism of benefit may be multifactorial, including repopulation of normal colonic flora and mechanical colonic decompression. Although our patient died, her case provides a framework for clinicians to consider this therapy and the expected response.
- Dificid (fidaxomicin) / Merck (MSD), Astellas
Cost-Effectiveness Analysis of Starting a Fecal Microbiota Transplantation (FMT) Unit for the Treatment of Recurrent C. difficile Infection Compared With Antibiotic Therapy (Exhibit Halls 3 and 4 (Street Level)) - Aug 8, 2019 - Abstract #ACG2019ACG_1496;
In our base case analysis of all three FMT modalities treating 40 patients/year compared with vancomycin, FMT via enema was the most cost-effective strategy with an incremental cost-effectiveness rate (ICER) of $21,366.03, followed by ICERs of $37,911.01, and $37,743.24 via capsule and colonoscopy, respectively. Treatment with fidaxomicin in these patients was both more expensive and less effective than FMT, as it was dominated by all 3 FMT modalities.
- Flagyl (metronidazole) / SLA
Clostridioides difficile Enteritis Refractory to Multiple Fecal Microbiota Transplantions (Exhibit Halls 3 and 4 (Street Level)) - Aug 8, 2019 - Abstract #ACG2019ACG_1312;
Over the next year, she had multiple recurrences of her CDI that failed vancomycin, fidaxomicin and IV immunoglobulin (IVIG)...Oral metronidazole has been used, with oral vancomycin used for refractory cases...Our case is unusual given the ongoing symptoms in a PCR negative CDI state. Further research is needed in patients with refractory CDI enteritis with analysis of their bowel flora to better understand this disease and how to treat it
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Xeljanz (tofacitinib) / Pfizer
Refractory Fulminant Ulcerative Colitis With Concurrent Clostridioides difficile Colitis Challenging Modern Guideline-Directed Medical Therapy to Failure (Exhibit Halls 3 and 4 (Street Level)) - Aug 8, 2019 - Abstract #ACG2019ACG_1010;
He had IBD-related arthritis & was started on sulfasalazine then methotrexate (MTX)...Despite IV steroids, infliximab, & tofacitinib; sulfasalazine & MTX; parallel PO vancomycin, fidaxomicin, IVIG & FMT, along with lactobacillus acidophilus, bloody diarrhea continued; patient was dependent on fluid support & blood transfusions...Safety & efficacy of the various treatments including immunosuppressants & FMT in cases of concurrent UC & CDI is a grey zone. Further case-reports & studies are needed to establish the optimal stepwise approach & guide therapeutic choice & decision making.
- Flagyl (metronidazole) / SLA
Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Patients Above 75 Years of Age: A Tertiary Center Experience (Exhibit Halls 3 and 4 (Street Level)) - Aug 8, 2019 - Abstract #ACG2019ACG_582;
Baseline characteristics of both groups are described in Table1. Number of CDI before FMT, history of severe CDI, nosocomial CDI were similar.
- Flagyl (metronidazole) / SLA
Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection: Efficacy and Predictors of Success (Exhibit Halls 3 and 4 (Street Level)) - Aug 8, 2019 - Abstract #ACG2019ACG_581;
The mean age at FMT was 57 years (19-92 years). There were 96% Caucasians and 76% of females.
- Flagyl (metronidazole) / SLA
Kinetics of Stool Polymerase Chain Reaction in Clostridioides difficile Infection and Its Utility in Predicting Recurrence (Stars at Night Ballroom) - Aug 8, 2019 - Abstract #ACG2019ACG_244;
Initial treatment was MET in 50% (25), VAN in 44% (22), both MET and VAN in 4% (2) and fidaxomicin in 2% (1). Median treatment duration was 14 (range 8-60) days.
- | Dificid (fidaxomicin) / Merck (MSD), Astellas
Enrollment open, Trial completion date, Trial primary completion date: Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile Infection (clinicaltrials.gov) - Aug 5, 2019
P3, N=50, Recruiting, Sponsor: McMaster University
Median treatment duration was 14 (range 8-60) days. Active, not recruiting --> Recruiting | Trial completion date: Jun 2018 --> Jun 2022 | Trial primary completion date: Dec 2017 --> Dec 2021
- | Retrospective data, Journal: The prevalence of antibiotic-resistant Clostridium species in Iran: a meta-analysis. (Pubmed Central) - Aug 3, 2019
Metronidazole and vancomycin, as the first-line therapies, fidaxomicin, tetracyclines (except tetracycline), rifampicin and chloramphenicol can still be used for the treatment of C. difficile infections. However, the present results do not recommend the use of penicillin, bacitracin and tetracycline for the treatment of C. perfringens infections in humans and domestic animals in Iran.
- | Dificid (fidaxomicin) / Merck (MSD), Astellas
Journal: Outcomes With Fidaxomicin Therapy in Clostridium difficile Infection. (Pubmed Central) - Jul 26, 2019
All patients with a first CDI episode treated with fidaxomicin responded with no recurrences. Patients with prior CDI episodes were less likely to respond (especially with more than 1 prior episode) and more likely to recur, suggesting a greater clinical benefit of fidaxomicin earlier in the course of CDI.
- | Flagyl (metronidazole) / SLA
Retrospective data, Journal: Which Antimicrobial Agent is Likely to be the Best for Treating Clostridium difficile Infections? A Bayesian Network Meta-Analysis of Randomized Clinical Trials. (Pubmed Central) - Jul 24, 2019
To conclude, teicoplanin and fidaxomicin have been observed to perform better than other antimicrobials for the treatment of CDI. We recommend conducting high quality randomized controlled clinical trials evaluating teicoplanin and fidaxomicin with other standard interventions for the management of CDI.
- | Dificid (fidaxomicin) / Merck (MSD), Astellas
Journal: Fidaxomicin jamsRNA polymerase motions needed for initiation via RbpA contacts. (Pubmed Central) - Jul 19, 2019
The results establish that Fdx acts like a doorstop to jam the enzyme in an open state, preventing the motions necessary to secure promoter DNA in the active site. Our results provide a structural platform to guide development of anti-tuberculosis antimicrobials based on the Fdx binding pocket.
- | Dificid (fidaxomicin) / Merck (MSD), Astellas
Preclinical, Journal: Impact of oral fidaxomicin administration on the intestinal microbiota and susceptibility tocolonization in mice. (Pubmed Central) - Jul 17, 2019
Bacterial diversity was similar prior to antibiotic exposure in both arms and decreased substantially after exposure. A shift in taxonomic structure and composition occurred after both exposures; however, the shift was greater in vancomycin- than in fidaxomicin-exposed mice.In summary, compared with vancomycin, fidaxomicin exposure had less impact on microbiota composition, promoted faster microbial recovery and had less impact on loss ofcolonization resistance.
- ||| Dificid (fidaxomicin) / Merck (MSD), Astellas
Reimbursement, Medicare: Surely Medicare and private insurance will not cover it that easily? I saw this with the intro of Fidaxomicin (C. diff Rx) at ridiculous costs. We had to have several failures of Vanco before Dificid was covered and even then it was tough. (Twitter) - Jul 7, 2019
- | Flagyl (metronidazole) / SLA
Clinical, Retrospective data, Journal: Clinical and microbiological characteristics of Clostridium difficile infection in children hospitalized at the Departement of Paediatric Infectious Diseases in Brno between 2013 and 2017. (Pubmed Central) - Jul 6, 2019
Fidaxomicin was well tolerated by all patients. We prefer the treatment with fidaxomicin in high-risk groups (immunocompromised condition, inflammatory bowel disease, and short bowel syndrome).
- | Dificid (fidaxomicin) / Merck (MSD), Astellas
Biomarker, Journal: Organic Solute Transporter OSTα/ß is Over-Expressed in Nonalcoholic Steatohepatitis and Modulated by Drugs Associated with Liver Injury. (Pubmed Central) - Jul 5, 2019
The interaction study with 26 compounds revealed novel OSTα/β inhibitors: a biomarker for cholestasis, glycochenodeoxycholic acid; the major metabolite of troglitazone, troglitazone sulfate; and a macrocyclic antibiotic, fidaxomicin...Additionally, some drugs (e.g., digoxin) consistently stimulated taurocholate uptake in OSTα/β overexpressing cells. Our findings demonstrate that OSTα/β is an important transporter in liver disease, and implicate a role for this transporter in bile acid-bile acid and drug-bile acid interactions, as well as cholestatic DILI.
- | Dificid (fidaxomicin) / Merck (MSD), Astellas
Enrollment open, Trial primary completion date: Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection (clinicaltrials.gov) - Jun 30, 2019
P2, N=30, Recruiting, Sponsor: University of Alberta
Our findings demonstrate that OSTα/β is an important transporter in liver disease, and implicate a role for this transporter in bile acid-bile acid and drug-bile acid interactions, as well as cholestatic DILI. Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2020 --> Dec 2021
- || Dificid (fidaxomicin) / Merck (MSD), Astellas
Fidaxomicin is another antibiotic alternative. (Twitter) - Jun 23, 2019
- |||| Dificid (fidaxomicin) / Merck (MSD), Astellas
Es una buena opción sin embargo las ultimas guías de la IDSA lo dejan como una opción si no hay fidaxomicina o vancomicina #SoMe4Surgery (Twitter) - Jun 23, 2019
- | vancomycin / generics
Preclinical, Journal: Tapering Courses of Oral Vancomycin Induce Persistent Disruption of the Microbiota that Provide Colonization Resistance toand Vancomycin-Resistant Enterococci in Mice. (Pubmed Central) - Jun 22, 2019
In contrast, mice treated with a 10-day course of vancomycin exhibited recovery of the microbiota and of colonization resistance by 15 days after treatment, and fidaxomicin-treated mice maintained intact colonization resistance. These findings demonstrate that alteration of the indigenous microbiota responsible for colonization resistance toand VRE persist during and after completion of tapering courses of vancomycin.
- | Flagyl (metronidazole) / SLA
Clinical, Journal, HEOR: Cost-effectiveness analysis of initial treatment strategies for mild-to-moderate Clostridium difficile infection in hospitalized patients. (Pubmed Central) - Jun 22, 2019
From the hospital perspective, initial treatment with vancomycin resulted in a higher probability of cure and a lower probability of colectomy, recurrence, persistent recurrence, and cost per case treated, compared with metronidazole. Use of fidaxomicin was associated with an increased probability of cure compared with metronidazole and vancomycin, but at a substantially increased cost.
- || Dificid (fidaxomicin) / Merck (MSD), Astellas
My biggest barrier to fidaxomicin use is lack of insurer approval When I get it we find it helpful (Twitter) - Jun 20, 2019
- | Dificid (fidaxomicin) / Merck (MSD), Astellas
Fidaxomicina> Metronidazol+Vancomicina. para evitar el trasplante. (Twitter) - Jun 14, 2019
- | Dificid (fidaxomicin) / Merck (MSD), Astellas
Journal: Recommendations from a panel of experts on the usefulness of fidaxomicin for the treatment of infections caused by Clostridium difficile (Pubmed Central) - Jun 5, 2019
Use of fidaxomicin was associated with an increased probability of cure compared with metronidazole and vancomycin, but at a substantially increased cost. The experts consulted showed a high degree of agreement on topics related to the selection of patients with poorer prognosis, as well as on the use of fidaxomicin in groups of high-risk patients, either in the first line or in situations of recurrence.
- | Dificid (fidaxomicin) / Merck (MSD), Astellas
Clinical, Journal: Single centre clinical experience with fidaxomicin in the treatment of Clostridium difficile infection in Slovakia. (Pubmed Central) - May 26, 2019
Only one of three patients, with three or more recurrences of CDI, had no further presentations after eight weeks of completion of treatment. The biggest benefit from fidaxomicin treatment was shown in a cohort of patients with primary CDI infection demonstrating a low recurrence rate and significant reduction of fidaxomicin effectiveness in preventing a recurrence when treating patients with multiple rCDI.
- | Dificid (fidaxomicin) / Merck (MSD), Astellas
Journal: Fidaxomicin and Fecal Microbiota Transplants for Severe Clostridium difficile Colitis. (Pubmed Central) - May 24, 2019
The biggest benefit from fidaxomicin treatment was shown in a cohort of patients with primary CDI infection demonstrating a low recurrence rate and significant reduction of fidaxomicin effectiveness in preventing a recurrence when treating patients with multiple rCDI. No abstract available
- | Dificid (fidaxomicin) / Merck (MSD), Astellas
Journal: Characterization of the impact of rpoB mutations on the in vitro and in vivo competitive fitness of Clostridium difficile and susceptibility to fidaxomicin. (Pubmed Central) - May 22, 2019
Our study demonstrates that particular SNPs in rpoB lead to reduced fidaxomicin susceptibility. These mutations were associated with a fitness cost in vitro and reduced virulence in vivo.
- | Dificid (fidaxomicin) / Merck (MSD), Astellas, Zinplava (bezlotoxumab) / Merck (MSD)
Journal, HEOR: Cost-effectiveness of three different strategies for the treatment of first recurrent Clostridium difficile infection diagnosed in a community setting. (Pubmed Central) - May 22, 2019
Vancomycin alone appears to be the most cost-effective regimen for the treatment of first recurrence of CDI. Fidaxomicin alone led to the highest QALY gained, but at a cost beyond what is considered cost-effective.